Sudip Bandyopadhyay advises caution in pharma due to US tariff uncertainties, recommending domestic-focused companies like Mankind Pharma for growth. He also anticipates a strong Q3 for value retailers, including V-Mart, driven by rising incomes and festive demand. Overall, domestic sectors offer safer growth amidst global volatility.
Nifty can cross 32K in 2026 bull case scenario: Kotak Securities
In a recent note, domestic brokerage firm Kotak Securities has projected a bull case target of 32,032 for the Nifty 50 index by December 2026,